Information Provided By:
Fly News Breaks for June 9, 2015
ONCY
Jun 9, 2015 | 13:44 EDT
Piper Jaffray said it views Oncolytics' newly announced plans to prioritize REOLYSIN development in bladder and brain cancers as a deviation from its prior registrational plans. Following the announcement, the firm downgraded the stock to Neutral from Overweight and cut its price target on the shares to 75c from $1.50.
News For ONCY From the Last 2 Days
There are no results for your query ONCY